SARCOMED
SarcoMed develops therapeutic solutions for treating chronic pulmonary inflammation. SarcoMed's lead product candidate, SM001, is a recombinant form of human deoxyribonuclease I (DNase I), with a proven mechanism of action and a differentiated clinical profile. SarcoMed was founded in 2017.
SARCOMED
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.sarcomedusa.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Content Delivery Network Wordpress Plugins Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.sarcomedusa.com
- Host name: 118.0.153.160.host.secureserver.net
- IP address: 160.153.0.118
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "SarcoMed"
SarcoMed - Crunchbase Company Profile & Funding
SarcoMed develops therapeutic solutions for treating chronic pulmonary inflammation. SarcoMed's lead product candidate, SM001, is a recombinant …See details»
SarcoMed USA - Overview, News & Similar companies
View SarcoMed USA (www.sarcomedusa.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Sarcomedusa | VentureRadar
HiLung Japan Privately Held Our company was founded to develop, optimize, and commercialize novel therapies for respiratory diseases through new science based on "pulmonary stem cell …See details»
SARCOMEDUSA INC. - Texas Company
Business Details of SARCOMEDUSA INC. in TexasSARCOMEDUSA INC. (Texas Tax ID: 32064821914) was incorporated on 09/13/2017 in Texas. Their business is recorded as …See details»
ABOUT US - smed.richkidandco.com
ABOUT US SarcoMedUSA was formed to investigate if an inhaled DNase 1 therapy could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients. …See details»
About Us - sarcomedusa.com
ABOUT US SarcoMedUSA was formed to investigate if an inhaled DNase 1 therapy could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients.See details»
SarcoMed USA, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore SarcoMed USA, Inc. with its drug pipeline, therapeutic area, technology platform, 6 news, Disease Domain:Nervous System Diseases, Technology Platform:Hormone ...See details»
SARCOMEDUSA LLC Houston TX, 77056 - Company Profile - Cortera
Free Business profile for SARCOMEDUSA LLC at 1300 Post Oak Blvd, Houston, TX, 77056-3094, US. SARCOMEDUSA LLC specializes in: Commercial Physical and Biological Research.See details»
OUR TEAM - smed.richkidandco.com
Igor Gonda David Moller M.D. Wajdie Ahmad ABOUT SARCOMED USA SarcoMedUSA was formed to investigate if an inhaled DNase 1 therapy could influence the chronic pulmonary …See details»
Sarcomedusa | VentureRadar
SarcoMed USA was formed in 2017 to investigate if a novel DNase 1 compound (SM001) could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients. …See details»
Our Team - sarcomedusa.com
Leveraging our leadership team’s proven expertise in discovering and developing groundbreaking medicines from emerging biological fields, we are applying their combined knowledge to …See details»
SarcoMed USA - 2025 Company Profile & Competitors - Tracxn
May 18, 2025 SarcoMed USA is an unfunded company based in Houston (United States), founded in 2017. It operates as a Developer of therapeutic solutions for treating chronic …See details»
Contact us - sarcomedusa.com
SarcoMed USA is comprised of experienced biotech entrepreneurs with strong drug development expertise, including Sarcoidosis clinical advisors. The company has initiated a human open …See details»
NATIONALLY RECOGNIZED DRUG DEVELOPMENT EXPERTS
SarcoMedUSA, INC. formed in 2017 was developed to determine if SM001 could improve Pulmonary Sarcoidosis. SarcoMed has assembled a nationally recognized team of drug …See details»
Drug Test - sarcomedusa.com
Formed in 2017, SarcomedUSA, Inc. “Sarcomed” is led by experienced biotech entrepreneurs with strong drug development backgrounds and respected expert clinical advisors. Below is …See details»
Companies Enter Non-binding Deal to Develop Sarcoidosis Therapy
Jul 30, 2020 Protalix BioTherapeutics and SarcoMed USA have entered into a non-binding agreement to develop PRX-110 (alidornase alfa) for pulmonary sarcoidosis.See details»
Sarcomedusa - VentureRadar
Associated sectors: Biotechnology; Pulmonary Sarcoidosis; Sarcoidosis; DNase 1; Respiratory; Alveolus Bio USA Privately Held Alveolus Bio is pursuing the development of novel FDA …See details»
Brian Davies - sarcomedusa.com
SarcoMedUSA was formed to investigate if an inhaled DNase 1 therapy could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients.Proof‐of‐Concept …See details»
WHAT IS SARCOIDOSIS? - sarcomedusa.com
Sarcoidosis is an inflammatory disease that can affect any organ and involves the lungs in 90 percent of patients. The tissue biopsy of patients with sarcoidosis has a characteristic …See details»